[go: up one dir, main page]

WO2005115423A1 - Utilisation de potassium organique et/ou inorganique et de ses sels pour traiter l'auto-immunite et d'autres troubles de la sante, methodes pour administrer ces substances - Google Patents

Utilisation de potassium organique et/ou inorganique et de ses sels pour traiter l'auto-immunite et d'autres troubles de la sante, methodes pour administrer ces substances Download PDF

Info

Publication number
WO2005115423A1
WO2005115423A1 PCT/IN2004/000149 IN2004000149W WO2005115423A1 WO 2005115423 A1 WO2005115423 A1 WO 2005115423A1 IN 2004000149 W IN2004000149 W IN 2004000149W WO 2005115423 A1 WO2005115423 A1 WO 2005115423A1
Authority
WO
WIPO (PCT)
Prior art keywords
potassium
organic
administration
group
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2004/000149
Other languages
English (en)
Inventor
Munisekhar Medasani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP04735493A priority Critical patent/EP1763357A1/fr
Priority to PCT/IN2004/000149 priority patent/WO2005115423A1/fr
Priority to CA002567637A priority patent/CA2567637A1/fr
Publication of WO2005115423A1 publication Critical patent/WO2005115423A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • the present invention relates to a use of organic forms of Potassium salts in a dietary supplement, and in pharmaceutical and cosmetic preparations that are effective for the treatment of autoimmune disorders like psoriasis, eczema, multiple sclerosis etc and other health disorders like potassium deficiency, hypertension, heart problem, kidney stones, cancer etc by elevating/correcting total body potassium levels and improving efficiency of Potassium pumps like Sodium-Potassium pumps etc of human body.
  • This invention also relates to the use and method of administration of Banana peel extract, source of organic form of Potassium salts, alpha-adrenergic agonists (norepinephrine (NE)), vasoconstrictors and menthol in topical applications.
  • NE alpha-adrenergic agonists
  • This invention further relates to the use and method of administration of organic and inorganic forms of Potassium salts with alpha-adrenergic agonists (norepinephrine (NE)), vasoconstrictors and menthol in topical applications.
  • alpha-adrenergic agonists no-adrenergic agonists
  • NE alpha-adrenergic agonists
  • vasoconstrictors vasoconstrictors and menthol in topical applications.
  • the inventor herein has realized the effect of potassium deficiency on autoimmune disorders like psoriasis and started taking potassium in organic form to saturate the total body potassium levels. Once it started working for them, they started searching for any products and logics available to support their finding. They came across a US Patent filed by Oge, et al (US Patent 5,955,067) in which Oge, et al described the clearance of psoriasis by using potassium rich tube feeding formula with hospitalized patients which due to various medical surgical or neurological impairments lost their ability to receive oral feedings. Oge, et al also describe clinical trials on otherwise healthy individuals in controlled conditions to saturate total body potassium level. May be in view of problems associated with the hyperkalemia Oge, et al suggested attaining local saturation of potassium levels at the effected area of the skin by topical intradermic route. BACKGROUND OF THE INVENTION
  • Potassium (K) is one of the minerals (also referred to as electrolytes) in the body. Potassium is the most abundant intracellular cation. Almost 98% of the potassium content of a healthy body is found inside the cells. Only about 2% of total body potassium is extracellular. Since most intracellular potassium is contained within muscle cells, total body potassium content is rouglily proportional to lean body mass. An average 70-kg adult has about 3500 mEq of potassium. Potassium is a major determinant of intracellular osmolality. The relationship between intra- and extracellular fluid potassium concentrations strongly influences cell membrane polarization, which in turn influences important cell processes, such as the conduction of nerve impulses and muscle (including myocardial) cell contraction.
  • Potassium is important to maintain several bodily functions. Potassium is required to regulate pressure between the inside and outside of cells. The same will be done though Sodium-Potassium Pump. With inadequate potassium, cellular wastes are not efficiently transported into the extracellular spaces and carried away. Toxic material is left to accumulate in the cell can cause premature cell death. Potassium is needed to convert blood sugar into glycogen for storage in the liver and muscles. With inadequate glycogen storage humans will not have strength and will quickly become exhausted physically and mentally. Potassium is also required for pH balance of blood, body water balance for maintaining, blood pressure.
  • Potassium stimulates insulin production, digestive enzyme function and efficiency, nerve and muscle function. Potassium acts to relax muscle contraction in balance to calcium which induces contraction. Many causes, such as utilization of medications like steroids, non-potassium sparing diuretics, some penicillins, exogenous bicarbonate ingestion, Amphotericin B, Gentamicin, physical and psychological stress, excess Sodium (Na) intake, can cause depletion of total body potassium levels. With age, total body potassium level decreases. This decrease reflects the decrease in lean body muscle mass, which contains about 75% of intracellular potassium. Although aldosterone secretion decreases with age, the kidney's ability to regulate potassium excretion under normal dietary conditions is unaffected.
  • Urinary potassium excretion of 10 mEq/24 h represents near maximal renal potassium conservation and, therefore, implies significant potassium depletion.
  • Inorganic form of potassium in tablet form containing more than lOOmg per dose cannot be taken without a doctor's prescription, as per US FDA guidelines, due to the side affects associated with sudden rise in serum potassium levels and GI track ulcerations.
  • Other options available are Potassium Powders to be taken with liquids, and IV administration, which are mostly prescription medicines. When doctors prescribe potassium supplements, it is usually in the range of 1,500 to 3,000 mg/day.
  • Banana powder is available in the market. But dry banana powder contains 88.28% of carbohydrates (USD A National Nutrient Database). Individuals who do not want to gain weight or who are on low carbohydrate diets do not prefer this high carbohydrate content. Bananas in other than natural form are used for many home remedies, as detailed in the Medicinal Plants of the World, Vol-2, Page 320. The bananas are used in urban areas are mainly for the children who are suffering with diarrhea; to overcome" dehydration. Bananas are also used in ready to serve foods for kids, in food preparations and as flavoring agent.
  • banana drinks are available, but contains less of the natural fruit, more of added additives, excipients, preservatives and sugars, these may not be a good dietary source of potassium.
  • Raw Banana is used in Ayurveda Medication (Indian Traditional Medicine) for ages as an effective astringent and is recommended widely as a diet for treating diarrhea.
  • hi Homeopathy they use Kali-arsenicum, Kali-bromatum, Kali-Sulphuricum which are potassium salts for treating psoriasis, but these are used along with elements such as sulphur, mercury.
  • Kali-arsenicum, Kali-bromatum, Kali-Sulphuricum which are potassium salts for treating psoriasis, but these are used along with elements such as sulphur, mercury.
  • sulphur, mercury for some people homeopathy is effective in treating psoriasis, but for many it is difficult to follow the strict diet and alcohol restrictions they suggest.
  • Potassium works synergistically with sodium in the body. However our typical intake of potassium vs. sodium is considered wrong. A fresh fruit and vegetable diet has a hundred times more potassium than sodium. researchers recommend an intake of at least 5 times more potassium than sodium. As per the Article in The American Journal of Clinical Nutrition (Am J Clin Nutr 2000; 71: 1020-6), Late Paleolithic diets used to contain 6,970mg of Potassium and 604mg of Sodium, which is a 12:1 ratio. Unfortunately, most modern diets have so much salt that they reverse the ratio with Potassium: Sodium being about 0.7:1. Added salt is 95% of our dietary sodium.
  • An Average American diet consists of 3,400mg of Sodium against minimum requirement of 500mg and 2,400 mg of Potassium against a requirement of 3,500mg.
  • Most of our convenience foods have added salt (sodium chloride), monosodium glutamate (MSG) for taste purpose.
  • salt sodium chloride
  • MSG monosodium glutamate
  • the body expects abundant potassium and less sodium. Eating vegetables and fruits in raw form is the best way of getting the potassium required for the body. Excess potassium cannot be stored in the body, excess potassium will be excreted in 1-2 hrs to maintain the proper serum potassium level. It is know that stress depletes potassium from the body. Stress can take many forms: taking an examination, recovering from a broken bone, or maintaining proper levels of energy substrates in the face of even mild starvation.
  • body potassium levels will deplete due to many reasons, which also includes stress.
  • stress is increasing for human beings, which causes depletion of body potassium levels on a continuous basis, causing health problems.
  • Stress can potentially contribute to many diseases like high blood pressure, diabetes, heart problems, cancer, GI track acidity and ulceration, autoimmune disorders like psoriasis, eczema etc.
  • convenience foods have more sodium and minimum/nil potassium. Due to the adverse reaction associated with the oral intake of inorganic potassium and as per the FDA guidelines, 99mg per tablet is not enough to replenish body potassium loss on a 'regular basis' unless one adopts to a regular intake of fresh fruits and vegetables.
  • This invention provides convenience and a less time consuming way of administration of more than lOOmg of Potassium (organic and inorganic) without possible side effects associated with the present oral dosages, with the administration being in the form of a food supplement, pharmaceutical or cosmetic. Accordingly, a food source which is high in a natural or organic potassium content is first dehydrated in a known manner to remove water to a substantial degree, i.e.
  • the potassium rich extract may be administered in the form of a powder, granules, tablets, caplets, capsule, Effervescent tablet, Effervescent powder, chewable tablet, chewing gum, drink mix, suspension, enteric coated tablets, enteric coated granules, sustained release tablets.
  • a preferred food source for this operation is bananas or plantains, and/or their roots, pulp, peel, stalk, leaves, stem, suckers, flowers, where these are from the botanical family Musaceae of the order Zingiberales and its genera: Musa.
  • the extraction potassium rich extract may be formulated into a pharmaceutical topical applications for treating autoimmune and other skin diseases like, but not limited to, psoriasis, atopic dermatitis, eczema.
  • any pharmaceutically acceptable potassium salt of organic or inorganic form may be fabricated into a transdermal patch for administering 100 to 7,000 mg per day and even more preferably 100 to 3,000mg per day of potassium to the user.
  • the inventor herein has realized the effect of potassium deficiency on autoimmune disorders like psoriasis and started taking potassium in organic form to saturate the total body potassium levels. Once it started working for them, they started searching for any products and logics available to support their finding. They came across a US Patent filed by Oge, et al (US Patent 5,955,067) in which Oge, et al described the clearance of psoriasis by using potassium rich tube feeding formula with hospitalized patients which due to various medical surgical or neurological impairments lost their ability to receive oral feedings. Oge, et al also describe clinical trials on otherwise healthy individuals in controlled conditions to saturate total body potassium level.
  • the present invention differs from that of Oge,et al in its form of administration and its focus, i.e. attaining saturation of total body potassium levels on a regular basis.
  • the present invention also works as a preventive measure for many autoimmune and other diseases.
  • the physiologic components of the adaptation include the ability to excrete a potassium load more quickly (renal potassium secretion rates are markedly enhanced) and the temporary storage of potassium in the intracellular fluid is more effective.
  • plasma potassium levels do not rise to the same degree in the potassium-adapted animal as they do in the non-adapted animal.
  • the mechanism(s) responsible for potassium adaptation are not well understood. There is evidence that diets high in potassium result in increased aldosterone secretion rates, increased insulin release, the induction of larger amounts of Na K ATPase in the cells of the renal tubule and the large intestine.
  • the potassium secretion capacity of the distal nephron (specifically the distal half of the distal convoluted tubule and the cortical collecting tubule) is markedly enhanced in animals on high potassium intake and this enhancement can be shown to characterize the function of the isolated nephron segment in vitro as well as in vivo.
  • this enhancement can be shown to characterize the function of the isolated nephron segment in vitro as well as in vivo.
  • the mechanism which is affecting autoimmune disorders like psoriasis, eczema etc due to low total body potassium is not understood clearly, it was noticed that by increasing the daily intake of potassium and attaining the saturation of total body potassium levels the conditions of disease improved and also other conditions like gouts, bone degeneration, hypertension, insomnia etc the inventor was facing along with psoriasis were corrected.
  • a food source which is high in a natural or organic potassium content is first dehydrated in a known manner to remove water to a substantial degree, i.e. freeze dried; the so dehydrated food source is then reduced to small particles and the carbohydrate content thereof is extracted there from by a solvent in which carbohydrates are more soluble but proteins and organic potassium compounds are not, such as aqueous ethanol; the residue that remains after carbohydrate extraction is dried of solvent yielding a potassium rich extract which is used in pharmaceuticals, food supplements, food products and cosmetics to supplement the body's intake of potassium without possible side effects.
  • the potassium rich extract may be administered in the form of a powder, granules, tablets, caplets, capsule, Effervescent tablet, Effervescent powder, chewable tablet, chewing gum, drink mix, suspension, enteric coated tablets, enteric coated granules, sustained release tablets.
  • a preferred food source for this operation is bananas or plantains, and/or their roots, pulp, peel, stalk, leaves, stem, suckers, flowers, where these are from the botanical family Musaceae of the order Zingiberales and its genera: Musa.
  • the extraction potassium rich extract may be formulated into a pharmaceutical topical applications for treating autoimmune and other skin diseases like, but not limited to, psoriasis, atopic dermatitis, eczema.
  • any pharmaceutically acceptable potassium salt of organic or inorganic form may be fabricated into a transdermal patch for administering 100 to 7,0000mg per day and even more preferably 100 to 3,000mg per day of potassium, to the user.
  • the potassium rich food source that may be used include, but is not limited to, bananas, avocados, orange, prunes, apricots, mangos, raisins, dates etc; from vegetables like potato, sweet potato, tomato, spinach etc; from seeds lima beans, fried beans, soya beans, sunflower seeds, almonds etc.
  • bananas as an example, a 100 g banana comprises about 75.1 g water, 1.2 g protein, 0.3 g fat, 23.2 g carbohydrates and 400 mg potassium.
  • the dried residue which remains is a mass of about 1.7 g that mainly comprises the natural potassium salt and protein content of the original banana.
  • the resulting potassium rich extract contains moisture from 3% to 15% and may be pulverized to particle size less than 250 microns. Consumption of about 10-50g of such a potassium rich extract over the course of a day in the form of powder, granules, tablet, caplet, capsule, Effervescent tablet, Effervescent powder, chewable tablet, chewing gum, drink mix, suspension, enteric coated tablets, enteric coated granules, sustained release tablets, etc. supplies 3,000mg per day of potassium to the user.
  • potassium rich extract may be supplemented with vitamins, minerals, flavoring agents, fibers, coloring agents, and or taste improvers.
  • Such potassium rich extract may be formulated into a lotion, cream, ointment, emulsion, solution, patch, cleanser, conditioner, gel, soap, sprays, foam, cosmetic and tape which may then be applied as a topical application for treating autoimmune and other skin diseases like, but not limited to, psoriasis, atopic dermatitis, eczema.
  • Such potassium rich extract may be formulated into a pharmaceutically acceptable transdermal patch for administering 100 to 7,000 mg per day and even more preferably 100 to 3,000mg per day, by any pharmaceutically acceptable patch making technologies.
  • potassium rich extract forms of potassium other than that obtained from such potassium rich extract may be used, such as inorganic potassium salts, homeopathic salts (like Kali-Sulphuricum etc), ayurvedic salts of potassium or a combination thereof.
  • inorganic potassium salts like Kali-Sulphuricum etc
  • homeopathic salts like Kali-Sulphuricum etc
  • the skin is structured to prevent loss of essential body fluids.
  • the Adult Human body contains water at about 60% of body weight.
  • Adult human skin contains about 60-65% of water, hi the absense of stratum corneum we would all lose significant amounts of water to the environment, and rapidly become dehydrated.
  • the skin is a vital part of the body's temperature regulation system, protecting us against hypothermia and hyperthermia. There is a continuous loss of water from the skin even at low temperatures. Probably about 4/5 th of this outward transport of water takes place through the sweat glands, but the droplets are so small and evaporation so rapid that they cannot be seen with the naked eye. The reminding 1/5 1 is lost transepidermally.
  • Lipid soluble substances such as vitamins A and D, Steriod Hormones, Salicylic Acid etc penetrate the skin with ease. It is probable that the major pathway of this absorption is through the hair follicles and the sebaceous glands (F.J.Ebling).
  • Scalp consists of 5 layers of which the first three are the skin, connective tissue and epicranial aponeurosis. These three layers are bound together as single unit.
  • Connective tissue (superficial fascia) provides a passage way for nerves and blood vessels. Blood vessels are attached to this fibrous connective tissue. If the vessels are cut, this attachment prevents vasospasm, which could lead to profuse bleeding after injury. Wounds in the scalp bleed profusely because the fibrous fascia prevents vasoconstriction.
  • the head and upper truck have more sebaceous glands than other parts of the body.
  • scalp psoriasis occurs in at least 50 percent of all people with psoriasis and dermatologists think scalp psoriasis is a special kind that won't go away easily, in The world conference on Psoriasis.
  • a previously unrecognized pharmacological event, acute tolerance to the vasoconstrictive action of topically applied glucocorticosteroids has been discovered in human skin.
  • potent topical glucocorticosteroids will cause vasoconstriction when first applied to human skin but with subsequent applications the production of vasoconstriction rapidly diminishes.
  • glucocorticoids minimize the water loss from the skin. Hairs grow out of tubular invaginations of the epidermis known as follicles, and a hair follicle and its associated sebaceous glands are referred to as a pilosebaceous unit. Hair follicles extend into the dermis at an angle.
  • Arrector pili muscles are supplied by adrenergic nerves, and are responsible for the erection of hair during cold or emotional stress ('goose flesh').
  • the sebaceous gland is attached to the follicle just above the point of attachment of the arrector pili. (www.telemedicine.org).
  • hypothalamus is the principal region in the cetral nervous system where the afferent pathways from temperature sensors act upon efferent pathways to thermoregulatory effectors by which autonomic and somatic nevers and endocrine glands make appropriate responses.
  • the anterior region of the hypothalamus is principally involved in the control of responses to the warm environment (sweating, increased skin blood flow) and that the posterior region is principally involved in the control of responses to cold (shivering, vasoconstriction).
  • M.W.Stanier et al Other finding by Suskind.R.R.(1954) and Christine Kronauer (2001) identified that one of the major functions of psoriatic lesion is preventing water loss and sweat retention in the body. From above it is clear that by reducing the body water loss i.e. by vasoconstriction we can control the psoriasis.
  • Phenylephrine which is used for nasal decongestant, on psoriasis affected scalp area.
  • Phenylephrine is an Adrenergic Agent that mimics the sympathetic neurotransmitter norepinephrine (NE).
  • NE norepinephrine
  • Psoriatic skin has responded well to that and lesions reduced. This worked by way of reducing water loss of psoriatic skin by vasoconstriction.
  • NE norepinephrine
  • the extract of banana peel will be beneficial for treating skin diseases like psoriasis, atopic dermatitits, eczema etc by activating the cold nerves.
  • the Filtrate A and B were taken into a distillation unit and distilled 75% of its volume under reduced pressure and temperature not exceeding 90 degrees C. 600 ml of alcohol was added and cooled to the room temperature to precipitate. The precipitate was filtered and washed the cake with aqueous alcohol. The filtrate and washing were collected together and evaporated to dryness. The dry residue was washed with alcohol till the material stickiness is lost and further dried in a dryer to yield 15grams of dried potassium rich extract. The dried potassium rich extract was analyzed for the potassium, total sugars and moisture were determined by Atomic Emission Spectrometry, HPLC using refractory index detector, desiccation at 105 degrees C respectively. Results were as under: Potassium content — 11.25% Total Sugars - 23.70% Moisture - 1.62%
  • Transdermal patches 5 cm in diameter is prepared for the delivery of potassium chloride.
  • the patches are composed of a tri-lamihate of an adhesive matrix sandwiched between an occlusive backing layer and a release liner.
  • the adhesive matrix is prepared from the pressure sensitive silicone adhesive together with potassium chloride.
  • the occlusive backing film is a polyester film (about 3.00 mil in thickness).
  • the release liner is a polyester film (about 3.0 mil in thickness).
  • the final transdermal patch is about 16 mil thick, 5 cm in diameter and has a surface area of about 10 cm.
  • the transdermal patch is applied to a patient by removing the release liner and contacting the adhesive unit with the skin to supply 300mg of potassium in 6 hrs. While certain novel features of this invention have been shown and described and mentioned in the claims, it is not intended to be limited to the details above, since it will be understood that various omissions, modifications, substitutions and changes in the forms and details of the device illustrated and in its operation can be made by those skilled in the art without departing in any way from the spirit of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition de potassium de source organique, une préparation, une méthode d'administration et une quantité à administrer pour traiter des troubles auto-immunes, ainsi qu'une supplémentation sous forme de préparation. Une source alimentaire à haute teneur en potassium organique ou naturel est d'abord déshydratée pour en extraire l'eau à un degré substantiel, par exemple par lyophilisation. La source alimentaire ainsi déshydratée est alors réduite en petites particules et la teneur en hydrate de carbone de celles-ci est extrait par un solvant dans lequel les hydrates de carbone sont plus solubles, alors que les protéines et les composés de potassium organique ne le sont pas, par exemple l'éthanol aqueux. Les restes subsistant après extraction des hydrates de carbone sont séchés par solvant et utilisés dans des produits pharmaceutiques, des compléments alimentaires, des produits alimentaires et cosmétiques pour augmenter l'absorption en potassium sans effets secondaires éventuels.
PCT/IN2004/000149 2004-05-31 2004-05-31 Utilisation de potassium organique et/ou inorganique et de ses sels pour traiter l'auto-immunite et d'autres troubles de la sante, methodes pour administrer ces substances Ceased WO2005115423A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04735493A EP1763357A1 (fr) 2004-05-31 2004-05-31 Utilisation de potassium organique et/ou inorganique et de ses sels pour traiter l'auto-immunite et d'autres troubles de la sante, methodes pour administrer ces substances
PCT/IN2004/000149 WO2005115423A1 (fr) 2004-05-31 2004-05-31 Utilisation de potassium organique et/ou inorganique et de ses sels pour traiter l'auto-immunite et d'autres troubles de la sante, methodes pour administrer ces substances
CA002567637A CA2567637A1 (fr) 2004-05-31 2004-05-31 Utilisation de potassium organique et/ou inorganique et de ses sels pour traiter l'auto-immunite et d'autres troubles de la sante, methodes pour administrer ces substances

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000149 WO2005115423A1 (fr) 2004-05-31 2004-05-31 Utilisation de potassium organique et/ou inorganique et de ses sels pour traiter l'auto-immunite et d'autres troubles de la sante, methodes pour administrer ces substances

Publications (1)

Publication Number Publication Date
WO2005115423A1 true WO2005115423A1 (fr) 2005-12-08

Family

ID=35450654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000149 Ceased WO2005115423A1 (fr) 2004-05-31 2004-05-31 Utilisation de potassium organique et/ou inorganique et de ses sels pour traiter l'auto-immunite et d'autres troubles de la sante, methodes pour administrer ces substances

Country Status (3)

Country Link
EP (1) EP1763357A1 (fr)
CA (1) CA2567637A1 (fr)
WO (1) WO2005115423A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100088252A1 (en) * 2006-10-19 2010-04-08 Le-Henand Herve Methods of providing long-term nutrition
WO2011018700A1 (fr) * 2009-08-12 2011-02-17 Munisekhar Medasani Extrait naturel de fruit de banane entier (musa spp.)
WO2012078798A1 (fr) * 2010-12-07 2012-06-14 Bananalogix, Inc. Procédés de traitement de la matière organique et compositions en contenant
WO2012030841A3 (fr) * 2010-08-30 2012-08-09 Bananalogix, Inc. Moyens améliorés de fourniture d'éléments essentiels et de nutriments
US9017748B2 (en) 2007-12-28 2015-04-28 Kraft Foods Group Brands Llc Potassium fortification in foodstuffs
CN106466388A (zh) * 2015-08-20 2017-03-01 哈尔滨灵草舒生物科技有限公司 一种灯芯草清心火沐浴泡腾片及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63283552A (ja) * 1987-05-15 1988-11-21 Iino Akira ブラジル原産白甘薯を主体とした健康食品
JPH0356424A (ja) * 1989-07-21 1991-03-12 Otsuka Shokuhin Kk カリウム補給用剤、その製法及びこれを含む飲食・医薬品
JPH11180879A (ja) * 1997-09-22 1999-07-06 L'oreal Sa バラ科植物エキスの用途
JP2003095967A (ja) * 2001-09-27 2003-04-03 Ichimaru Pharcos Co Ltd 抗アレルギー剤
EP1312373A1 (fr) * 2000-06-28 2003-05-21 Kikkoman Corporation Agents anti-allergiques, medicaments, aliments, boissons ou produits cosmetiques contenant ces agents et procedes permettant de produire ceux-ci

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63283552A (ja) * 1987-05-15 1988-11-21 Iino Akira ブラジル原産白甘薯を主体とした健康食品
JPH0356424A (ja) * 1989-07-21 1991-03-12 Otsuka Shokuhin Kk カリウム補給用剤、その製法及びこれを含む飲食・医薬品
JPH11180879A (ja) * 1997-09-22 1999-07-06 L'oreal Sa バラ科植物エキスの用途
EP1312373A1 (fr) * 2000-06-28 2003-05-21 Kikkoman Corporation Agents anti-allergiques, medicaments, aliments, boissons ou produits cosmetiques contenant ces agents et procedes permettant de produire ceux-ci
JP2003095967A (ja) * 2001-09-27 2003-04-03 Ichimaru Pharcos Co Ltd 抗アレルギー剤

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100088252A1 (en) * 2006-10-19 2010-04-08 Le-Henand Herve Methods of providing long-term nutrition
US9017748B2 (en) 2007-12-28 2015-04-28 Kraft Foods Group Brands Llc Potassium fortification in foodstuffs
WO2011018700A1 (fr) * 2009-08-12 2011-02-17 Munisekhar Medasani Extrait naturel de fruit de banane entier (musa spp.)
US8496977B2 (en) 2009-08-12 2013-07-30 Munisekhar Medasani Natural extract from whole banana fruit (Musa Spp)
EA028836B1 (ru) * 2009-08-12 2018-01-31 Мунисекхар Медасани Натуральный экстракт из цельных плодов банана (musa spp.)
WO2012030841A3 (fr) * 2010-08-30 2012-08-09 Bananalogix, Inc. Moyens améliorés de fourniture d'éléments essentiels et de nutriments
WO2012078798A1 (fr) * 2010-12-07 2012-06-14 Bananalogix, Inc. Procédés de traitement de la matière organique et compositions en contenant
CN106466388A (zh) * 2015-08-20 2017-03-01 哈尔滨灵草舒生物科技有限公司 一种灯芯草清心火沐浴泡腾片及其制备方法

Also Published As

Publication number Publication date
CA2567637A1 (fr) 2005-12-08
EP1763357A1 (fr) 2007-03-21

Similar Documents

Publication Publication Date Title
WO2008065457A2 (fr) Mélange d'herbes, substance active obtenue à partir de ce mélange et utilisation de cette substance active pour améliorer le métabolisme, pour renforcer l'immunité et pour favoriser un traitement
CN101966222A (zh) 一种具有壮骨功效的药物组合物、制剂及其制备方法
US20050170020A1 (en) Using organic and / or inorganic potassium and its salts to treat autoimmune and other health disorders and methods of administering the same
Hasan et al. Effect of fenugreek on type 2 diabetic patients
US10758578B2 (en) Herbal formulations of carnivorous plants and methods for treating inflammation
KR100455222B1 (ko) 다이어트 인삼복합제품 및 그 제조방법
WO2005115423A1 (fr) Utilisation de potassium organique et/ou inorganique et de ses sels pour traiter l'auto-immunite et d'autres troubles de la sante, methodes pour administrer ces substances
CN109069532A (zh) 含铬组合物用于改善健康和健身
Bhattacharya et al. Recent targeted discovery of phytomedicines to manage endocrine disorder develops due to adapting sedentary lifestyle
CN109045138A (zh) 一种辅助治疗痛风的复方芹菜籽片剂及其制备方法
CN109528968A (zh) 一种治疗2型糖尿病的中药组合物及其制备方法和应用
CN105982882B (zh) 一种光学活性原料组合物组方治疗痔疮的外用药及制备工艺
CN103181945B (zh) 丝瓜子的用途
CN114794478A (zh) 一种能降低血压血脂血糖的组合物及应用
RU2238755C1 (ru) Лечебно-профилактическое средство, обладающее гепатопротекторным, холестерино- и сахарорегулирующим действием (варианты)
KR100441308B1 (ko) 다이어트 인삼복합음료 및 그 제조방법
CN100450531C (zh) 一种治疗小儿遗尿的中药制剂
KR102706369B1 (ko) 글루타치온을 포함하는 미백용 액상형 조성물 및 이를 포함하는 건강기능성 식품
CN1921875B (zh) 以竹子提取物作为主要成分的饮料和药品
KR100834487B1 (ko) 대나무 추출물을 주성분으로 하는 음료 및 의약
JPH0798753B2 (ja) 血糖値降下のための組成物
KR20040092232A (ko) 성기능 개선용 홍삼복합물, 이의 제조방법 및 이의 용도
CN103689298B (zh) 用于治疗僵猪的饲料及其制备方法
CN102631496B (zh) 提高免疫力、抗疲劳的中药组合物
RU2139071C1 (ru) Средство для лечения хронического гепатита неинфекционной этиологии, осложненного хроническим панкреатитом

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2567637

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2004735493

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 4792/CHENP/2006

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2004735493

Country of ref document: EP